UK markets closed

NIKKEI 225
27,419.61
-47.00(-0.17%)
HANG SENG
20,049.64
+458.21(+2.34%)
CRUDE OIL
69.41
-1.49(-2.10%)
GOLD FUTURES
2,004.30
+54.70(+2.81%)
DOW
31,928.35
-101.76(-0.32%)
Bitcoin GBP
22,845.11
-307.16(-1.33%)

The DIAL CEO Activist Campaign

Leaders in business and politics discuss the push for inclusive culture in organisations

Akebia Therapeutics, Inc. (AKBA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Add to watchlist

0.6551

-0.0124

(-1.86%)

As of 02:53PM EDT. Market open.

Loading interactive chart…

Zacks
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 71.43% and 14.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Simply Wall St.
Akebia Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags
Akebia Therapeutics ( NASDAQ:AKBA ) Third Quarter 2022 Results Key Financial Results Revenue: US$49.0m (flat on 3Q...
Zacks
Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -86.67% and 3.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?